Asher Mullard
Nat. Rev. Drug Discov., 2019, 18(12), 887-891
https://doi.org/10.1038/d41573-019-00195-5

Abstract

Five anti-cancer KRAS inhibitors, with three different modes of action, are in the clinic. More are on the way.